{"mainPropery":{"diseaseId":9967,"diseaseName":"Sertoli-leydig cell tumors","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9967/sertoli-leydig-cell-tumors","synonyms":["Arrhenoblastoma","Androblastoma of ovary","Sertoli-leydig cell tumor of the ovary","Arrhenoblastoma of ovary"],"synonyms-with-source":[{"name":"Arrhenoblastoma"},{"name":"Androblastoma of ovary"},{"name":"Sertoli-leydig cell tumor of the ovary"},{"name":"Arrhenoblastoma of ovary"}],"identifiers":[]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":319,"resourceName":"Ovarian Cancer Research Alliance","abbreviation":"","address1":"14 Pennsylvania Plaza, Suite 2110","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10122","country":"United States","phone":"212-268-1002","tty":"","tollFree":"866-399-6262","fax":"202-331-2292","email":"info@ocrahope.org","url":"https://ocrahope.org","freeText":""},{"resourceID":320,"resourceName":"National Ovarian Cancer Coalition","address1":"2501 Oak Lawn Avenue, Suite 435","address2":"","address3":"","address4":"","address5":"","city":"Dallas","state":"TX","zip":"75219 ","country":"United States","phone":"214-273-4200 ","tty":"","tollFree":"888-OVARIAN","fax":"214-273-4201 ","email":"nocc@ovarian.org","url":"http://www.ovarian.org/"}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=Sertoli-Leydig%5BTitle%5D%20AND%20cell%5BTitle%5D%20AND%20tumor%5BTitle%5D%20AND%20ovary%5BTitle%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Sertoli-leydig cell tumors. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Sertoli-leydig+cell+tumors%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Sertoli-leydig cell tumors. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001507.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1627984-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1553,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://cis.nci.nih.gov' target='_blank'>National Cancer Institute</a> (CIS)  provides the most current information on cancer for patients, health professionals, and the general public. You can reach them by calling toll-free at 1-800-422-6237 or by visiting their Web site. ","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:2997' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Sertoli-leydig cell tumors. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Sertoli-leydig cell tumors:<br />\r\n<a href='https://www.otstregistry.org/' target='_blank'>International Ovarian and Testicular Stromal Tumor Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":3206,"questionText":"What are&nbsp;Sertoli-Leydig cell tumors? ","answerText":"<strong>Sertoli-Leydig cell tumors&nbsp;</strong>are a cancer that starts in the female ovaries. The cancer cells produce and release a male sex hormone which&nbsp;may cause the development of male physical characteristics (<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002339.htm\" target=_blank>virilization</a>), including facial hair and a deep voice.[2193]&nbsp;This type of tumor is sometimes called <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001507.htm\" target=_blank>arrhenoblastoma of the ovary</a>&nbsp;or a stromal tumor.[2193][2194]&nbsp;Sertoli-Leydig cell tumors are&nbsp;rare tumors&nbsp;which account for less than 0.5% of all ovarian tumors.&nbsp;While&nbsp;they can be found in women of all age groups,&nbsp;they&nbsp;are&nbsp;most common in young women.&nbsp;Treatment involves surgery and chemotherapy or radiation if the cancer has spread. Because&nbsp;Sertoli-Leydig cell tumors&nbsp;have a low chance of spreading, if the tumor is found early, chances for survival are good.[2194]","dateModified":"2010-03-25T17:32:00"},"basicQuestions":[{"questionId":6639,"questionText":"Can Sertoli-Leydig cell tumor of the ovary be inherited?","answerText":"There is evidence that some Sertoli-Leydig cell tumors of the ovary might be caused by a <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/predisposition\" target=_blank>genetic predisposition</a> to develop cancer.&nbsp; <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=_blank>Mutations</a> in the <a href=\"http://omim.org/entry/606241\" target=_blank>DICER1</a> gene have been associated with an increased chance to develop Sertoli-Leydig cell tumors of the ovary, as well as other types of cancer.[5721]&nbsp; It appears that mutations in DICER1 can be passed from a parent to a child in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=_blank>autosomal dominant</a> manner.[5720]","dateModified":"2013-01-01T11:30:00","resourceClassificationName":"Inheritance","references":[{"referenceId":5720,"authors":"Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'Brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen VH, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M","articleTitle":"DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors","bookWebsiteJournalTitle":"JAMA","date":"2011","volume":"305","pages":"68-77","url":"http://www.ncbi.nlm.nih.gov/pubmed/21205968","dateAccessed":"2013-01-01T00:00:00"},{"referenceId":5721,"authors":"Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D, Morland B, Pizer B, Prescott K, Saggar A, Side L, Traunecker H, Vaidya S, Ward P, Futreal PA, Vujanic G, Nicholson AG, Sebire N, Turnbull C, Priest JR, Pritchard-Jones K, Houlston R, Stiller C, Stratton MR, Douglas J, Rahman N","articleTitle":"DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome","bookWebsiteJournalTitle":"Journal of Medical Genetics","date":"2011","volume":"48","pages":"273-278","url":"http://www.ncbi.nlm.nih.gov/pubmed/21266384","dateAccessed":"2013-01-01T00:00:00"}]},{"questionId":6637,"questionText":"How might a Sertoli-Leydig cell tumor of the ovary be treated?","answerText":"Because Sertoli-Leydig cell tumors of the ovary are rare, there are no established guidelines for treatment.&nbsp; Treatment decisions are based on the unique characteristics of each tumor, particularly the <a href=\"http://www.cancer.gov/dictionary?CdrID=45885\" target=_blank>stage</a>.&nbsp; Surgery&nbsp;to remove&nbsp;the tumor is considered the&nbsp;best&nbsp;treatment for&nbsp;an early-stage tumor, whereas surgery and <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=_blank>chemotherapy</a> may be needed to treat a later-stage tumor.[5717][5718]","dateModified":"2013-01-01T11:26:00","resourceClassificationName":"Treatment","references":[{"referenceId":5717,"authors":"Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, Wan X, Xiang Y, Xiao Y, Guo L","articleTitle":"A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"127","pages":"384-389","url":"http://www.ncbi.nlm.nih.gov/pubmed/22850410","dateAccessed":"2013-01-01T00:00:00"},{"referenceId":5718,"authors":"Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi F, Cormio G, Marinaccio M, Mangili G","articleTitle":"Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"673-676","url":"http://www.ncbi.nlm.nih.gov/pubmed/22446621","dateAccessed":"2013-01-01T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":37546,"abbreviatedInquiry":"My 15 year old granddaughter has been diagnosed with a Sertoli-leydig cell tumor in her ovary.&nbsp;&nbsp;What are her chances of survival if it is a cancerous tumor?&nbsp; She also&nbsp;has nodules on her thyroid, and the doctors are planning to remove her&nbsp;thyroid.&nbsp; Her mother had the same thing, but it&nbsp;is in remission.","caseQuestions":[{"questionId":6636,"questionText":"What is the chance of survival in an individual diagnosed with a Sertoli-Leydig cell tumor?","answerText":"The chance of surviving a Sertoli-Leydig cell tumor of the ovary is quite high.&nbsp; The outlook is most favorable for individuals diagnosed at an early <a href=\"http://www.cancer.gov/dictionary?CdrID=45885\" target=_blank>stage</a>, meaning the cancerous cells have not spread into nearby healthy organs.[5717][5718]&nbsp; One study showed that 92% of individuals diagnosed with a&nbsp;Sertoli-Leydig cell tumor at an early stage were alive five years after their diagnosis compared to&nbsp;33% of individuals with&nbsp;tumors diagnosed at later stages.[5718]","dateModified":"2013-01-01T11:29:00","references":[{"referenceId":5717,"authors":"Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, Wan X, Xiang Y, Xiao Y, Guo L","articleTitle":"A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"127","pages":"384-389","url":"http://www.ncbi.nlm.nih.gov/pubmed/22850410","dateAccessed":"2013-01-01T00:00:00"},{"referenceId":5718,"authors":"Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi F, Cormio G, Marinaccio M, Mangili G","articleTitle":"Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"673-676","url":"http://www.ncbi.nlm.nih.gov/pubmed/22446621","dateAccessed":"2013-01-01T00:00:00"}]},{"questionId":6637,"questionText":"How might a Sertoli-Leydig cell tumor of the ovary be treated?","answerText":"Because Sertoli-Leydig cell tumors of the ovary are rare, there are no established guidelines for treatment.&nbsp; Treatment decisions are based on the unique characteristics of each tumor, particularly the <a href=\"http://www.cancer.gov/dictionary?CdrID=45885\" target=_blank>stage</a>.&nbsp; Surgery&nbsp;to remove&nbsp;the tumor is considered the&nbsp;best&nbsp;treatment for&nbsp;an early-stage tumor, whereas surgery and <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=_blank>chemotherapy</a> may be needed to treat a later-stage tumor.[5717][5718]","dateModified":"2013-01-01T11:26:00","resourceClassificationName":"Treatment","references":[{"referenceId":5717,"authors":"Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, Wan X, Xiang Y, Xiao Y, Guo L","articleTitle":"A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"127","pages":"384-389","url":"http://www.ncbi.nlm.nih.gov/pubmed/22850410","dateAccessed":"2013-01-01T00:00:00"},{"referenceId":5718,"authors":"Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi F, Cormio G, Marinaccio M, Mangili G","articleTitle":"Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"673-676","url":"http://www.ncbi.nlm.nih.gov/pubmed/22446621","dateAccessed":"2013-01-01T00:00:00"}]},{"questionId":6638,"questionText":"Is Sertoli-Leydig cell tumor of the ovary associated with thyroid nodules?","answerText":"Several articles in the medical literature have described an association between Sertoli-Leydig cell tumor&nbsp;of the ovary and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/007265.htm\" target=_blank>thyroid nodules</a>.[5719][5720]&nbsp; It is thought that they may be related through a <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/predisposition\" target=_blank>genetic predisposition</a>, namely a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=_blank>mutation</a> in the <a href=\"http://omim.org/entry/606241\" target=_blank>DICER1</a> gene.[5720]","dateModified":"2013-01-01T11:26:00","references":[{"referenceId":5719,"authors":"Chi M, Gilman AD, Iroegbu N","articleTitle":"Management of metastatic ovarian Sertoli-Leydig cell tumor with sporadic multinodular goiter: a case report and literature review","bookWebsiteJournalTitle":"Future Oncology","date":"2011","volume":"7","pages":"1113-1117","url":"http://www.ncbi.nlm.nih.gov/pubmed/21919698","dateAccessed":"2013-01-01T00:00:00"},{"referenceId":5720,"authors":"Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'Brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen VH, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M","articleTitle":"DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors","bookWebsiteJournalTitle":"JAMA","date":"2011","volume":"305","pages":"68-77","url":"http://www.ncbi.nlm.nih.gov/pubmed/21205968","dateAccessed":"2013-01-01T00:00:00"}]},{"questionId":6639,"questionText":"Can Sertoli-Leydig cell tumor of the ovary be inherited?","answerText":"There is evidence that some Sertoli-Leydig cell tumors of the ovary might be caused by a <a href=\"https://ghr.nlm.nih.gov/primer/mutationsanddisorders/predisposition\" target=_blank>genetic predisposition</a> to develop cancer.&nbsp; <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=_blank>Mutations</a> in the <a href=\"http://omim.org/entry/606241\" target=_blank>DICER1</a> gene have been associated with an increased chance to develop Sertoli-Leydig cell tumors of the ovary, as well as other types of cancer.[5721]&nbsp; It appears that mutations in DICER1 can be passed from a parent to a child in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=_blank>autosomal dominant</a> manner.[5720]","dateModified":"2013-01-01T11:30:00","resourceClassificationName":"Inheritance","references":[{"referenceId":5720,"authors":"Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'Brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen VH, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M","articleTitle":"DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors","bookWebsiteJournalTitle":"JAMA","date":"2011","volume":"305","pages":"68-77","url":"http://www.ncbi.nlm.nih.gov/pubmed/21205968","dateAccessed":"2013-01-01T00:00:00"},{"referenceId":5721,"authors":"Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D, Morland B, Pizer B, Prescott K, Saggar A, Side L, Traunecker H, Vaidya S, Ward P, Futreal PA, Vujanic G, Nicholson AG, Sebire N, Turnbull C, Priest JR, Pritchard-Jones K, Houlston R, Stiller C, Stratton MR, Douglas J, Rahman N","articleTitle":"DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome","bookWebsiteJournalTitle":"Journal of Medical Genetics","date":"2011","volume":"48","pages":"273-278","url":"http://www.ncbi.nlm.nih.gov/pubmed/21266384","dateAccessed":"2013-01-01T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Sertoli-leydig_cell_tumors"}